Clinical Report: Registry of Clinical Outcomes, Treatments, and Progression in Anti–IFN-γ Induced Immunodeficiency

Background

AIGA immunodeficiency is a rare condition characterized by the presence of autoantibodies against interferon-γ, leading to increased susceptibility to opportunistic infections. The condition is often underdiagnosed due to low clinical awareness and the absence of standardized management guidelines.

Data Highlights

No numerical data available in the source material.

Key Findings

• AIGA immunodeficiency is primarily seen in adults, often presenting after the age of 30-40.
• Patients typically experience severe infections due to compromised macrophage-mediated intracellular killing.
• Diagnostic confirmation involves detecting autoantibodies and measuring the inhibition of Stat1 phosphorylation.
• The AIGA-PROTECT registry aims to standardize testing and collect clinical data for better management of AIGA immunodeficiency.

Clinical Implications

Healthcare professionals should be aware of AIGA immunodeficiency as a potential cause of adult-onset immunodeficiency syndromes.

Conclusion

The establishment of the AIGA-PROTECT registry represents a significant step towards understanding and managing AIGA immunodeficiency.

Related Resources & Content

1. International Union of Immunological Societies, 2024 -- The 2024 update of IUIS phenotypic classification of human inborn errors of immunity
2. Frontiers, 2025 -- Anti-interferon-γ autoantibodies syndrome and opportunistic infections: systematic literature review
3. JAMA Network Open -- Prospective Registry of Outcomes, Treatment, and Clinical Trajectories for Anti–IFN-γ Immunodeficiency
4. Co-administration of immunomodulators enhances recovery from anti-drug antibody-induced loss of efficacy in anti-TNF treatment for inflammatory bowel disease
5. Clinical Rheumatology — Efficacy Comparison of TNF Inhibitors and IL-6 Receptor Inhibitors as Monotherapy or in Combination with Methotrexate in Biologic-Experienced Rheumatoid Arthritis Patients: Insights from the CorEvitas RA Registry
6. Journal of Gastroenterology — Initial Infliximab Trough Levels at Two Weeks Correlate with Induction Therapy Outcomes in Ulcerative Colitis: Findings from a Multicenter Randomized Controlled Trial and Subsequent Analysis
7. Journal of Crohn's and Colitis — Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry
8. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity - PMC
9. Frontiers | Anti-interferon-γ autoantibodies syndrome and opportunistic infections: systematic literature review
10. Prospective Registry of Outcomes, Treatment, and Clinical Trajectories for Anti–IFN-γ Immunodeficiency | Allergy and Clinical Immunology | JAMA Network Open | JAMA Network